Publication & Citation Trends
Publications
0 total
Interstitial lung disease associated with amrubicin in the treatment of patients with small cell lung cancer.
Cited by 1
Semantic Scholar
Multi-Trial Evaluation of Progression-Free Survival (PFS) as a Surrogate Endpoint for Overall Survival (OS) in First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC) OA
Cited by 16
Semantic Scholar
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). OA
Cited by 44
Semantic Scholar
Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): An intergroup trial of JCOG0803/WJOG4307L.
Cited by 43
Semantic Scholar
Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation OA
Cited by 32
Semantic Scholar
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. OA
Cited by 34
Semantic Scholar
A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605) OA
Cited by 35
Semantic Scholar
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. OA
Cited by 1,181
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(259)
Lung Cancer Research Studies
(205)
Cancer therapeutics and mechanisms
(165)
Lung Cancer Diagnosis and Treatment
(88)
Cancer Treatment and Pharmacology
(82)
Affiliations
Kanazawa University
AstraZeneca (United Kingdom)
University of Southern California
SHOWA Medical University
University of Copenhagen
External Profiles
Continue on JournalsHub
Put what you just read into practice with these free tools.